Zyla Life Sciences

Zyla Life Sciences, formerly Egalet, is a specialty pharma company focusing on pain management. The company develops a pipeline of abuse-resistant opioids that are nearing pivotal testing. It offers delivery technologies that enable the controlled release of drugs through the gradual erosion of a tablet and has optimized the abuse-deterrent properties that can be applied to a broad range of opioids and non-opioids.

Employee Rating

2.9More
StateClosed
TypeSubsidiary
Parent CompanyAssertio
HQWayne, PA, US
Founded1995
Websitezyla.com
Cybersecurity ratingAMore
Zyla Life Sciences was founded in 1995 and is headquartered in Wayne, PA, US

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Zyla Life Sciences

Stan Musial

Stan Musial

CFO
E. Blair Clark-Schoeb

E. Blair Clark-Schoeb

Senior Vice President, Communications
Karsten Lindhardt

Karsten Lindhardt

Chief Scientific Officer
Patrick Shea

Patrick Shea

Chief Commercial Officer
Show more

Zyla Life Sciences Office Locations

Zyla Life Sciences has an office in Wayne
Wayne, PA, US (HQ)
600 Lee Rd #100
Show all (1)

Zyla Life Sciences Financials and Metrics

Summary Metrics

Founding Date

1995

Total Funding

$42.2 m
In total, Zyla Life Sciences had raised $42.2 m. Zyla Life Sciences is a subsidiary of Assertio

Zyla Life Sciences Revenue

Zyla Life Sciences's revenue was reported to be $30.35 m in FY, 2018
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.9m22.8m17.0m26.1m30.4m

Revenue growth, %

1089%(26%)

Sales and marketing expense

16.3m27.9m35.5m33.7m

General and administrative expense

16.7m26.5m30.7m34.1m24.1m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q2, 2019Q3, 2019Q1, 2020

Revenue

805.0k959.0k1.7m2.7m3.5m4.7m5.4m6.3m6.7m6.3m7.4m8.2m22.0m22.4m19.1m

Sales and marketing expense

1.6m3.3m6.3m6.2m6.3m7.0m9.3m9.3m8.8m9.1m9.0m7.9m9.1m9.3m10.0m

General and administrative expense

3.3m4.7m4.2m4.9m5.8m5.5m6.0m8.9m8.0m8.5m12.5m6.8m7.1m6.7m5.6m7.4m6.0m7.5m

R&D expense

2.8m7.4m6.3m10.3m4.9m4.6m6.1m8.7m12.1m6.5m4.6m2.1m1.3m999.0k956.0k4.0k3.0k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

52.7m46.7m44.4m31.1m35.3m12.0m

Accounts Receivable

1.0m295.0k1.1m4.1m8.0m25.7m

Prepaid Expenses

2.7m2.7m4.1m

Inventories

3.5m1.3m2.5m3.2m2.6m9.0m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(43.2m)(57.9m)(90.6m)(69.4m)(95.5m)

Depreciation and Amortization

641.0k3.0m4.1m5.1m4.2m

Inventories

3.9m(631.0k)(1.2m)(1.5m)429.0k

Accounts Payable

3.3m1.1m(2.9m)7.6m(1.6m)
USDQ1, 2014

Financial Leverage

1.2 x
Show all financial metrics

Zyla Life Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Zyla Life Sciences Online and Social Media Presence

Embed Graph

Zyla Life Sciences News and Updates

Assertio Completed Merger with Zyla Life Sciences

LAKE FOREST, Ill., May 20, 2020 /PRNewswire/ -- Assertio Holdings, Inc., the successor issuer to Assertio Therapeutics, Inc., ("Assertio" ) (NASDAQ: ASRT) announced the closing of the merger with Zyla Life Sciences. The combined company (the "Company") will operate under the Assertio name...

Zyla Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results

WAYNE, Pa., March 27, 2020 /PRNewswire/ -- Zyla Life Sciences (OTCQX: ZCOR) ("Zyla" or the "Company"), a commercial-stage life sciences company, today reported financial results for the fourth quarter and full year ended December 31, 2019, including net sales from commercial products:...

Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products

Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million1

Zyla Life Sciences Announces Management Changes

WAYNE, Pa., Oct. 23, 2019 /PRNewswire/ -- Zyla Life Sciences (OTCQX: ZCOR) ("Zyla"), a commercial-stage life sciences company, today announced that Robert Radie, has resigned as president, chief executive officer and director of the Company to pursue other opportunities. Mr. Radie will...

Egalet Reports Third Quarter 2018 Financial Results

WAYNE, Pa., Nov. 19, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain, today reported financial results for the third quarter ended...

Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products

WAYNE, Pa., Oct. 31, 2018 /PRNewswire/ -- Egalet Corporation (OTCQX: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain, today entered into an asset purchase agreement to acquire four...
Show more

Zyla Life Sciences Frequently Asked Questions

  • When was Zyla Life Sciences founded?

    Zyla Life Sciences was founded in 1995.

  • Who are Zyla Life Sciences key executives?

    Zyla Life Sciences's key executives are Stan Musial, E. Blair Clark-Schoeb and Karsten Lindhardt.

  • How many employees does Zyla Life Sciences have?

    Zyla Life Sciences has 130 employees.

  • What is Zyla Life Sciences revenue?

    Latest Zyla Life Sciences annual revenue is $30.4 m.

  • What is Zyla Life Sciences revenue per employee?

    Latest Zyla Life Sciences revenue per employee is $233.5 k.

  • Who are Zyla Life Sciences competitors?

    Competitors of Zyla Life Sciences include Cellarity, Brooks Life Sciences and Boston Analytical.

  • Where is Zyla Life Sciences headquarters?

    Zyla Life Sciences headquarters is located at 600 Lee Rd #100, Wayne.

  • Where are Zyla Life Sciences offices?

    Zyla Life Sciences has an office in Wayne.

  • How many offices does Zyla Life Sciences have?

    Zyla Life Sciences has 1 office.